In which clinical scenarios is conventional in‑vitro fertilization (IVF) preferred over intracytoplasmic sperm injection (ICSI), and vice versa?

IVF versus ICSI: Clinical Decision Algorithm

Conventional IVF should be the default method for all couples with non-male factor infertility (unexplained, tubal factor, PCOS) when the male partner has normal semen parameters, as it achieves equivalent or superior outcomes to ICSI at lower cost and with less invasiveness 1, 2.

Primary Decision Framework

Use Conventional IVF When:

• Normal semen parameters (TMSC >10 million post-wash) 3
• Unexplained infertility - ICSI provides no CLBR benefit and costs an additional $11 million per 2 years across SART clinics without improving outcomes 2
• Tubal factor infertility - conventional IVF shows significantly higher fertilization rates (78.63% vs 69.23%) 1
• PCOS - conventional IVF demonstrates higher fertilization (77.49% vs 68.81%) and more grade A embryos 1
• Poor ovarian response with normal sperm - no difference in clinical pregnancy, live birth, or cumulative outcomes 4
• Donor sperm cycles - ICSI shows higher fertilization but no clinical advantage, making the added cost unjustified 5

Use ICSI When:

• Severe male factor infertility:

  • TMSC <3 million pre-wash 3
  • Severe asthenozoospermia (≤5% rapid progressive motility) - conventional IVF has 50% complete fertilization failure rate 6
  • Severe oligozoospermia or teratozoospermia

• Previous total fertilization failure with conventional IVF 2

• Azoospermia requiring surgical sperm retrieval 7

• High sperm DNA fragmentation (after excluding modifiable risk factors and failed conservative treatments) - consider testicular sperm for ICSI on case-by-case basis 7

Critical Evidence Analysis

The most compelling recent evidence comes from the 2024 SART database analysis of 18,805 unexplained infertility cycles 2. This large-scale study definitively showed:

• No CLBR difference (54.4% ICSI vs 57.5% IVF without PGT-A)
• Higher miscarriage rate with ICSI (16.4% vs 14.4%)
• Lower 2PN per oocyte with ICSI (59.7% vs 60.9%)
• Number needed to treat: 35 patients require routine ICSI to prevent one total fertilization failure

The 2024 sibling oocyte study 1 provides the strongest evidence for PCOS, tubal factor, and unexplained infertility, demonstrating conventional IVF superiority in fertilization rates across all three groups with normal male parameters.

Cost-Effectiveness Hierarchy

Based on high-quality evidence 3:

1. First-line: IUI with ovarian stimulation (3-6 cycles) for TMSC >10 million and poor spontaneous pregnancy prognosis (<30% Hunault score)
2. Second-line: Conventional IVF after failed IUI
3. Reserve ICSI only for: Clear male factor indications

Common Pitfalls to Avoid

• Do not use ICSI routinely for advanced maternal age - no evidence of benefit 8
• Do not use ICSI for low oocyte numbers without male factor - no improvement in outcomes 4
• Do not assume ICSI is "safer" - emerging evidence suggests potential increased birth defect risk, though not conclusive 8
• Avoid ICSI in PGT-A cycles without male factor - no CLBR benefit (47.6% vs 51.8%) and higher cost 2

The 4% Risk Calculation

Total fertilization failure occurs in 4% of conventional IVF cycles vs 1.1% with ICSI 2. However, this 2.9% absolute risk reduction does not justify routine ICSI use given:

• No improvement in live birth rates
• Higher costs ($11+ million excess charges)
• Increased operator dependency and invasiveness
• Potential (though unproven) increased birth defect risk

The evidence overwhelmingly supports reserving ICSI exclusively for male factor infertility rather than using it as a "rescue" strategy for theoretical fertilization failure prevention.